Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors

Article Gastroenterology & Hepatology

Dasatinib-induced colitis: clinical, endoscopic and histological findings

Kenji Yamauchi et al.

Summary: Dasatinib, a second-generation tyrosine kinase inhibitor, is associated with the rare side effect of colitis, including haemorrhagic colitis and cytomegalovirus (CMV) colitis. In this retrospective study of 51 patients, 17.6% were diagnosed with dasatinib-induced colitis, characterized by mild diarrhea and bloody stools. Endoscopic findings included loss of vascular pattern and multiple small erosions mainly in the transverse and descending colon, with all patients being cured after discontinuing dasatinib.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2022)

Add to Collection

Review Oncology

FDA-Approved Drugs for Hematological Malignancies-The Last Decade Review

Aleksandra Sochacka-Cwikla et al.

Summary: This article summarizes the new drugs used in the treatment of hematological malignancies in the past decade, including small molecule and macromolecule agents. The development of these drugs has improved the clinical outcomes for blood cancers.

CANCERS (2022)

Add to Collection

Article Surgery

Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group

Carlos Solano et al.

Summary: The study found that CMV DNAemia was not associated with increased overall mortality and nonrelapse mortality in recipients of allogeneic hematopoietic stem cell transplantation. The use of preemptive antiviral therapy for CMV DNAemia was found to be associated with increased mortality in univariate models, but not in adjusted models. Further research is needed to confirm the potential impact of preemptive antiviral therapy on mortality.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Review Infectious Diseases

Risk of infection associated with targeted therapies for solid organ and hematological malignancies

Isabel Ruiz-Camps et al.

Summary: This review focuses on the higher risks of infection associated with targeted drugs used for solid organ and hematological malignancies, highlighting the significant impact of treatment on infection risk. Recommendations may be revised as therapies continue to advance.

THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE (2021)

Add to Collection

Letter Biophysics